Management of Fatigue Associated with Aripiprazole Long‑Acting Injectable (Abilify Maintena)

Adverse‑Effect Profile of the Depot Formulation

• Fatigue and somnolence are documented adverse effects of aripiprazole long‑acting injectable; the incidence is modestly lower than that reported for several other antipsychotics. 1

Systematic Evaluation of Reversible Contributors

• Before attributing fatigue solely to aripiprazole, obtain a complete blood count to screen for anemia, assess thyroid function, a comprehensive metabolic panel (electrolytes and calcium), and fasting glucose; correcting abnormalities can reverse fatigue. 2
• Review all concurrent medications for agents that may potentiate sedation (e.g., beta‑blockers, antihistamines, opioids, antidepressants, antiemetics) and consider deprescribing or timing adjustments. 2
• Screen for depression with a validated tool such as the PHQ‑9, because depressive symptoms can manifest primarily as fatigue. 2
• Evaluate sleep quality and screen for obstructive sleep apnea, especially in patients with recent changes in body composition or hormonal status. 2

Sleep‑Hygiene Strategies to Mitigate Fatigue

• Establish a consistent bedtime and wake‑time schedule, eliminate daytime napping, and maintain a dark, quiet, comfortable sleep environment. 2
• Avoid caffeine, alcohol, and high‑sugar foods in the evening; discontinue electronic device use at least one hour before sleep. 2
• Incorporate pre‑bedtime relaxation techniques (e.g., reading, journaling, yoga, meditation, or soft music) to reduce physiological arousal. 2

Pharmacologic Considerations

• Low‑dose oral aripiprazole (non‑depot) has shown promise for reducing fatigue in chronic‑fatigue‑syndrome populations, suggesting a dose‑dependent effect that may differ from depot‑induced fatigue. 3
• Antidepressants are not recommended solely for fatigue management; they should be used only when a comorbid depressive disorder is diagnosed. 4
• Psychostimulants such as methylphenidate have mixed and limited evidence of benefit, primarily in severe cancer‑related fatigue, and are not routinely advised for aripiprazole‑related fatigue. 4

Non‑Pharmacologic Interventions

• Supervised, tailored physical‑activity programs have demonstrated efficacy in reducing fatigue across diverse medical conditions; long‑term, regular exercise is preferred over short‑term bouts. 5
• Structured psychoeducational interventions that explore patients’ thoughts, feelings, and behaviors related to fatigue improve self‑management and perceived energy levels. 5
• Energy‑conservation techniques—prioritizing tasks, pacing activities throughout the day, delegating non‑essential duties, and maintaining a daily activity diary to identify peak energy periods—help mitigate fatigue. 6

Nutritional and Supplementary Measures

• Correct identified anemia with appropriate iron or vitamin supplementation; address electrolyte disturbances (sodium, potassium, calcium, magnesium) that can contribute to fatigue. 2
• Ensure adequate caloric intake and consider referral to a nutrition specialist when significant dietary abnormalities are present. 2
• Coenzyme Q10 and D‑ribose supplementation have shown promise as adjuncts in fatigue management, though evidence remains preliminary. [3][4]

Contraindication to Exercise in Specific Contexts

• Exercise should be avoided in patients with post‑exertional malaise, as it can exacerbate fatigue rather than improve it; this condition should be ruled out before initiating activity programs. 3

Evaluation and Management of Fatigue in Patients on Multiple Medications

Identify the Medication-Related Causes

• Tizanidine is a centrally-acting muscle relaxant with significant sedative properties that commonly causes drowsiness and fatigue as dose-dependent adverse effects, according to the American Academy of Child and Adolescent Psychiatry 7
• The American Academy of Child and Adolescent Psychiatry recommends assessing the current indication for tizanidine and whether it remains necessary—if muscle spasm or spasticity has improved, consider tapering or discontinuing this medication first 8
• Paroxetine commonly causes somnolence, asthenia (weakness), and fatigue as adverse effects, with incidences of 18-25% in clinical trials, as reported by the American Academy of Child and Adolescent Psychiatry 7, 8
• A discontinuation syndrome from paroxetine includes fatigue and lethargy, but this patient is currently taking the medication regularly, so this represents an ongoing adverse effect rather than withdrawal, according to the American Academy of Child and Adolescent Psychiatry 7, 8

Rule Out Other Contributing Factors

• Check thyroid function, complete blood count for anemia, comprehensive metabolic panel for electrolyte abnormalities, and glucose levels to rule out underlying medical causes of fatigue, as recommended by the American Academy of Child and Adolescent Psychiatry 7, 8
• Screen for depression despite the patient's report of no depressive symptoms—use a standardized tool like PHQ-9, as fatigue can be an isolated manifestation of depression, according to the Journal of Clinical Oncology 9

Stepwise Management Algorithm

• If clinically appropriate, initiate a gradual taper of tizanidine over 2-4 weeks while monitoring for return of muscle spasm symptoms, as recommended by the American Academy of Child and Adolescent Psychiatry 8
• Reassess fatigue after 2 weeks off tizanidine—if fatigue resolves, no further medication changes needed, according to the Annals of Oncology 10
• Consider switching to an SSRI with lower propensity for sedation, such as escitalopram or sertraline, if fatigue continues despite the above interventions and paroxetine remains necessary for anxiety control, as recommended by the American Academy of Child and Adolescent Psychiatry 7, 8

Important Caveats and Pitfalls

• Never stop paroxetine abruptly—it is specifically associated with discontinuation syndrome more than other SSRIs due to its shorter half-life, according to the American Academy of Child and Adolescent Psychiatry 7, 8
• Evidence shows that paroxetine does not reduce fatigue and antidepressants are not recommended for treating fatigue, as reported by the Annals of Oncology 10, 11, 12 and the Journal of the National Comprehensive Cancer Network 13 and the Journal of Clinical Oncology 9